Wall Street brokerages expect that BeyondSpring (NASDAQ:BYSI) will report ($0.73) earnings per share (EPS) for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have issued estimates for BeyondSpring’s earnings, with estimates ranging from ($0.73) to ($0.72). BeyondSpring posted earnings of ($2.66) per share in the same quarter last year, which would indicate a positive year over year growth rate of 72.6%. The business is scheduled to announce its next earnings results on Monday, May 28th.
According to Zacks, analysts expect that BeyondSpring will report full year earnings of ($2.80) per share for the current year, with EPS estimates ranging from ($2.92) to ($2.67). For the next financial year, analysts expect that the firm will post earnings of ($2.18) per share, with EPS estimates ranging from ($2.85) to ($1.51). Zacks Investment Research’s earnings per share averages are a mean average based on a survey of sell-side research firms that follow BeyondSpring.
BeyondSpring (NASDAQ:BYSI) last posted its earnings results on Tuesday, April 3rd. The company reported ($0.68) EPS for the quarter, missing analysts’ consensus estimates of ($0.62) by ($0.06).
Shares of NASDAQ:BYSI remained flat at $$27.05 during mid-day trading on Friday. The company had a trading volume of 12,039 shares, compared to its average volume of 5,905. The stock has a market capitalization of $607.43 and a P/E ratio of -6.15. BeyondSpring has a 12 month low of $19.55 and a 12 month high of $48.49.
BeyondSpring Company Profile
BeyondSpring Inc, a clinical stage biopharmaceutical company, focuses on the development of cancer therapies. The company is advancing its lead asset, Plinabulin, into a Phase 2/3 clinical trial for the reduction of docetaxel chemotherapy-induced severe, grade 4 neutropenia; a Phase 2/3 clinical trial for the prevention of non-docetaxel chemotherapy-induced severe, grade 4 neutropenia; a Phase 3 clinical trial as an anticancer agent in combination with docetaxel in advanced NSCLC; and Phase 1/2 clinical trials with the immuno-oncology agent nivolumab.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for BeyondSpring Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BeyondSpring and related companies with MarketBeat.com's FREE daily email newsletter.